Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 4:55 pm Purchase | 13G | DBV TECHNOLOGIES S.A. ADR DBVT | BRAIDWELL LP | 10,162,961 9.990% | 10,162,961 (New Position) | View |
| 2024-02-14 4:06 pm Sale | 13G | DECIPHERA PHARMACEUTICALS INC DCPH | BRAIDWELL LP | 2,385,623 2.920% | -2,213,861 (-48.13%) | View |
| 2024-02-14 4:06 pm Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BRAIDWELL LP | 0 0.000% | -3,469,674 (Position Closed) | View |
| 2024-02-14 4:06 pm Purchase | 13G | DBV TECHNOLOGIES S.A. ADR DBVT | BRAIDWELL LP | 9,885,328 9.990% | 503,047 (+5.36%) | View |
| 2023-02-14 4:07 pm Purchase | 13G | DBV TECHNOLOGIES S.A. ADR DBVT | BRAIDWELL LP | 9,382,281 9.990% | 9,382,281 (New Position) | View |
| 2023-02-14 4:06 pm Purchase | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BRAIDWELL LP | 3,469,674 6.450% | 3,469,674 (New Position) | View |
| 2023-02-14 4:06 pm Purchase | 13G | DECIPHERA PHARMACEUTICALS INC DCPH | BRAIDWELL LP | 4,599,484 6.680% | 4,599,484 (New Position) | View |